In India, Covaxin is one of the three vaccine candidates against the coronavirus disease (Covid-19) which is being developed. It has been approved for skin trials by the Central Drugs Standard Control Organisation (CDSCO).
Covaxin is a wholly-inactivated vaccine candidate that was jointly developed by Bharat Biotech and Indian Council of Medical Research’s National Institute of Virology in Pune.
The Phase I trials are conducted on a small group of volunteers to determine safety, dosage and learn about the immune response it generates while the next stage, Phase II trials, involves a larger number of healthy volunteers typically in the 100s or less to learn more about safety and effectiveness of the vaccine, said Dr Priya Sampathkumar, an infectious diseases specialist with US’ Mayo Clinic.
